dr. S.G. (Sjoerd) Elias

dr. S.G. (Sjoerd) Elias

Associate Professor
dr. S.G. (Sjoerd) Elias
  • Epi Kanker Team C
  • Julius Center Research Program Cancer
  • Julius Center Research Program Cancer

Research Programs

Strategic Program Cancer



I obtained my MSc in Clinical Epidemiology at the Netherlands Institute for Health Sciences (2002), and my PhD at Utrecht University (2003). Following graduation from Medical School in 2005 I worked as a resident in radiology (Gelre Ziekenhuizen Apeldoorn, the Netherlands, 2006-2007). A personal Dutch Cancer Society Research Fellowship (2009-2013) enabled me to work as a visiting scientist at the Molecular Imaging Program at Stanford (professor SS Gambhir), the Department of Radiology and Biomedical Imaging at the University of California San Francisco (professor NM Hylton), and the Department of Molecular Pathology at the Netherlands Cancer Institute (professor LJ van't Veer). Since 2008, I work as a Clinical Epidemiologist in the research programs Cancer and Methodology at the Julius Center for Health Sciences and Primary Care, since 2018 as Associate Professor. Furthermore, I have more than ten years of experience in teaching and coordinating courses in clinical epidemiology, both nationally as well as internationally. Since 2020 I am coordinator of the PhD program Clinical and Translational Oncology, and since 2021 I am coordinator of the Research Program Cancer and management team member of the Epidemiology department of the Julius Center, as well as board member of the UMC Utrecht Strategic Program Cancer.

Interests and Focus

My main research focus is on the clinical evaluation and translation of biomarkers, particularly for cancer classification (i.e. diagnostic, prognostic, and predictive markers). These markers include emerging imaging technologies such as molecular imaging, omics-based tests, and organoids. I have both experience in preclinical research as well as applied clinical science, and have expertise and experience in the design and analysis of studies spanning all (translation) phases of biomarker development, as well as treatment studies (from phase I through phase III).

Side Activities

- Board member of the UMC Utrecht Strategic Program Cancer.

- Coordinator of the Research Program Cancer of the Julius Center.

- Coordinator of the PhD program Clinical and Translational Oncology.

- Coordinator of the SUMMA course "Wetenschappelijke Vorming - Onderzoeksmethodologie" ("applied clinical research").

- Coordinator of the MSc Epidemiology course "Advanced Topics in Causal Research: Confounding and Effect-Modification".

- Member of the Internal Review Committee Exploration of the Dutch Cancer Society.

- Member of the Dutch Association for Epidemiology (Vereniging voor Epidemiologie), Registration as Senior Epidemiologist (B) (SMBWO, 2006).

Fellowship and Awards

2022: Voted best lecturer of the year by the Selective Utrecht Medical Master program students, Utrecht University

2016-2017: Jury member of the Talma Eykman award, UMC Utrecht.

2016-2017: Jury member of the Frits de Waard Penning, UMC Utrecht.

2014: Epidemiology teacher of the year, Epidemiology department, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht.

2014: Voted best lecturer of the year by the Selective Utrecht Medical Master program students, Utrecht University.

2013-2016: Methodologist of the Medical Ethical Review Board of the UMC Utrecht.

2013: UMC Utrecht Research Talent Program.

2012: Invitee, 2nd Inspire2Live annual conference at the Royal Netherlands Academy of Arts and Sciences (meeting of talented young international cancer scientists).

2011: René Vogels Foundation travel grant.

2009: Dutch Cancer Society Research Fellowship (four year personal grant).

Research Output (186)

Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI:Protocol of the LIMA study-a multicentre prospective observational cohort study

Janssen Liselore M., Suelmann Britt B.M., Elias Sjoerd G., Janse Markus H.A., Van Diest Paul J., Van Der Wall Elsken, Gilhuijs Kenneth G.A. 20 Sep 2022, In: BMJ Open. 12 , p. 1-8

MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes:a systematic review and meta-analysis

Janssen L. M., den Dekker B. M., Gilhuijs K. G.A., van Diest P. J., van der Wall E., Elias S. G. 19 Sep 2022, In: npj Breast Cancer. 8 , p. 1-7

Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review

Ter Maat Laurens S, van Duin Isabella A J, Elias Sjoerd G, van Diest Paul J, Pluim Josien P W, Verhoeff Joost J C, de Jong Pim A, Leiner Tim, Veta Mitko, Suijkerbuijk Karijn P M 9 Sep 2022, In: European Journal of Cancer. 175 , p. 60-76 17 p.

Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer:A proof-of-concept study

Peters Niek A., Constantinides Alexander, Ubink Inge, van Kuik Joyce, Bloemendal Haiko J., van Dodewaard Joyce M., Brink Menno A., Schwartz Thijs P., Lolkema Martijn P.J.K., Lacle Miangela M., Moons Leon M., Geesing Joost, van Grevenstein Wilhelmina M.U., Roodhart Jeanine M.L., Koopman Miriam, Elias Sjoerd G., Borel Rinkes Inne H.M., Kranenburg Onno 6 Sep 2022, In: Frontiers in oncology. 12

Detection of Experimental Colorectal Peritoneal Metastases by a Novel PDGFRβ-Targeting Nanobody

Strating Esther, Elias Sjoerd, van Scharrenburg Guus, Luoto Kaisa, Verheem André, Borel Rinkes Inne, Steen Herman, Kranenburg Onno Sep 2022, In: Cancers. 14

Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging

Strating Esther, Wassenaar Emma, Verhagen Mathijs, Rauwerdink Paulien, van Schelven Susanne, de Hingh Ignace, Rinkes Inne Borel, Boerma Djamila, Witkamp Arjen, Lacle Miangela, Fodde Riccardo, Volckmann Richard, Koster Jan, Stedingk Kris, Giesel Frederik, de Roos Remmert, Poot Alex, Bol Guus, Lam Marnix, Elias Sjoerd, Kranenburg Onno 1 Jul 2022, In: British Journal of Cancer. 127 , p. 145-155 11 p.

External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort

Bolhuis Karen, Wensink G. Emerens, Elferink Marloes A.G., Bond Marinde J.G., Dijksterhuis Willemieke P.M., Fijneman Remond J.A., Kranenburg Onno W., Borel Rinkes Inne H.M., Koopman Miriam, Swijnenburg Rutger Jan, Vink Geraldine R., Hagendoorn Jeroen, Punt Cornelis J.A., Elias Sjoerd G., Roodhart Jeanine M.L. 10 May 2022, In: Cancers. 14 , p. 1-17

Esophageal second primary tumors in patients with head and neck squamous cell carcinoma:incidence, risk factors and overall survival

Overwater Anouk, Rueb Kuna, Elias Sjoerd G, de Bree Remco, Weusten Bas L A M 25 Feb 2022, In: American Journal of Gastroenterology. 117 , p. 794-797 4 p.

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

Laoukili Jamila, Constantinides Alexander, Wassenaar Emma C E, Elias Sjoerd G, Raats Danielle A E, van Schelven Susanne J, van Wettum Jonathan, Volckmann Richard, Koster Jan, Huitema Alwin D R, Nienhuijs Simon W, de Hingh Ignace H J T, Wiezer René J, van Grevenstein Helma M U, Rinkes Inne H M Borel, Boerma Djamila, Kranenburg Onno 22 Feb 2022, In: British Journal of Cancer. 126 , p. 1824-1833 10 p.

Endoscopic intermuscular dissection for deep submucosal invasive cancer in the rectum:a new endoscopic approach

Moons Leon Mg, Bastiaansen Barbara, Richir Milan, Hazen W L, Tuynman Jurriaan, Elias Sjoerd G, Schrauwen R W M, Vleggaar Frank P, Dekker Evelien, Bos Philip, Farina Sarasqueta Arantza, Lacle M M, Hompes Roel, Didden Paul 24 Jan 2022, In: Endoscopy. 54 , p. 993-998 6 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet